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URINARY/KIDNEY DISORDERS – Clinical Outcomes Studies
PUK1
INCIDENCE AND COST OF ADVERSE EVENTS (AES) IN PATIENTS 
WITH RENAL CELL CARCINOMA (RCC) TREATED WITH 
ANGIOGENESIS INHIBITORS (AIS)
Dial E1, Duh MS1, Antras L1, Rodermund D1, Neary MP2, Choueiri TK3, Oh WK4
1Analysis Group, Inc., Boston, MA, USA, 2GlaxoSmithKline, Collegeville, PA, USA, 
3Dana-Farber Cancer Institute/Brigham and Women’s Hospital, Boston, MA, USA, 4Mount 
Sinai School of Medicine, New York, NY, USA
OBJECTIVES: The incidence of AEs and the costs associated with the management 
of those AEs have not been widely studied in patients with RCC receiving bevacizu-
mab, sorafenib, or sunitinib. This study evaluates these outcomes using a large claims 
database. METHODS: Patients with ≥ 2 RCC claims (ICD-9 189.0, 198.0) were 
identiﬁed in a large US commercial insurance claims database from 1/02 through 
12/08. Patients were observed and analyzed during the time of their ﬁrst AI treatment 
with bevacizumab, sorafenib, or sunitinib. AEs were deﬁned as diagnoses that were 
treatment-emergent (i.e., diagnoses not present in the 6 months prior to initiation of 
AI treatment). The incidence rate (IR) and mean cost per visit for each AE were cal-
culated in the outpatient, inpatient and ER settings. Cost data represented actual 
payments made by insurers. RESULTS: The inclusion criteria identiﬁed 269 bevaci-
zumab, 375 sorafenib, and 672 sunitinib patients. The three most frequent AEs 
experienced by patients in each treatment group were identiﬁed based on the overall 
IR. The setting-speciﬁc IRs and costs per visit for these AEs are: bevacizumab: outpa-
tient = 20.3/$1,522, 16.1/$652, 11.6/$91; inpatient = 3.9/$8,222, 1.5/$15,848, 
1.4/$4,808; ER = 3.8/$643, 0.7/$24, 0.8/$176 for anemia, lung diseases, and hyperten-
sion, respectively; sorafenib: outpatient = 24.1/$525, 19.2/$226, 11.0/$288; inpatient 
= 1.1/$8,205, 3.7/$6,104, 1.6/$18,001; ER = 0/$0, 2.3/$218, 10.3/$294 for lung 
diseases, hypertension, and abdominal pain, respectively; sunitinib: outpatient = 
31.1/$176, 26.5/$990, 23.3/$1,183; inpatient = 3.7/$13,183, 0.4/$30,843, 
2.7/$13,727; ER = 7.6/$409, 0/$0, 2.0/$606 for hypertension, lung diseases, and 
anemia, respectively. For outpatient treatment, there was a trend for IRs for each of 
the AEs to be the highest for sunitinib. CONCLUSIONS: Bevacizumab, sorafenib, and 
sunitinib were associated with frequent AEs, in particular abdominal pain, anemia, 
hypertension, and lung diseases. Management of these and other AEs resulted in 
signiﬁcant medical treatment costs. These results can be used in economic evaluations 
of various currently available targeted therapies for RCC.
PUK2
RETROSPECTIVE DATABASE EVALUATION OF PATIENT 
CHARACTERISITICS AND HEALTH CARE UTILIZATION OF MEMBERS 
WITH STAGE 3 CHRONIC KIDNEY DISEASE WITH ANEMIA
Prasla K1, Godley PJ1, DSylva L2
1Scott & White Health Plan, Temple, TX, USA, 2American Regent, Shirley, NY, USA
OBJECTIVES: Chronic Kidney Disease (CKD) is a signiﬁcant health care problem in 
the United States; iron deﬁciency anemia can greatly impact resource utilization. We 
compared patient and health characteristics and health care utilization of members 
with stage 3 CKD with anemia versus without anemia in a regional integrated health 
care system. METHODS: Patients 18 and older were identiﬁed with a calculated GFR 
between 30 and 59 ml/min/1.73m3 (stage 3) using the MDRD equation or ICD-9 
diagnosis code of 585.3 between July 1, 2004 and June 30, 2007. Patients were 
required to be continuously enrolled for 6 months pre- and 24 months post-index 
dates. Anemia patients were identiﬁed with ICD-9 codes (280.0–280.9, 285.21, 
285.29, or 285.9) or hemoglobin values (<13, male; <12, female). Dialysis patients 
were excluded. Descriptive and inferential statistics were utilized. RESULTS: 2,739 
patients met inclusion criteria; 24% (n = 648) had anemia. 8.4% (n = 231) of patients 
were identiﬁed by ICD-9, while 17% (n = 113) of anemia patients had the above 
ICD-9 codes. Mean age was 73.3 and 71.5 years (p < 0.001) for with anemia and 
without anemia groups, respectively. 58% and 27% of anemia patients had comorbid 
hypertension and diabetes, respectively, versus 50% and 19% in the without anemia 
group. Per patient visit to nephrology, inpatient, and ED were as follows: 0.52, 4.33, 
and 0.53 for anemia, 0.19, 1.74, and 0.28 for without anemia (p < 0.001). Average 
health care costs during the post-index period was 59% higher (p < 0.001) for anemia 
patients versus patients without anemia. 8% of anemia patients progressed to stage 4 
versus 4.5% for without anemia patients. 20.1% (n = 130) of anemia patients were 
treated with either an erythropoietin stimulating agent (14.5%) or intravenous iron 
therapy (5.6%); 3.9% (n = 25) were treated with both. CONCLUSIONS: CKD 
remains under-diagnosed and patients with anemia utilize more resources compared 
to CKD patients without anemia; however, anemia remains under-treated.
PUK3
EVALUATION OF SIMULTANEOUS LIVER KIDNEY TRANSPLANTATION 
VERSUS LIVER TRANSPLANTATION ALONE FOR END-STAGE LIVER 
DISEASE PATIENTS WITH IMPAIRED RENAL FUNCTION – A 
COMPARATIVE EFFECTIVENESS ANALYSIS
Chang Y, Skaro AI, Jay C, Manheim LM
Northwestern University, Chicago, IL, USA
OBJECTIVES: Simultaneous liver kidney (SLK) transplant improves the survival of 
liver transplant candidates with renal insufﬁciency. The indication for SLK transplant 
remains controversial due to potential renal recovery after liver transplant alone 
(LTA). This study aims to (1) investigate the difference in survival between SLK and 
LTA recipients and (2) estimate the additional number of kidney grafts utilized for 
SLK transplant. METHODS: The Markov decision model was constructed to simulate 
a hypothetical cohort of liver transplant candidates with impaired renal function to 
receive either (1) LTA or (2) SLK transplant strategy. Transplant candidates in each 
strategy were categorized into 4 groups, based on the Model for End-Stage Liver 
Disease (MELD) score. LTA recipients without recovering renal function within three 
months post-transplant were subsequently placed on the kidney transplant waiting 
list. Liver re-transplant and kidney re-transplant were considered in the model for 
acute and chronic graft failure post-transplant. The simulation period was 10 years. 
Microsimulations were conducted to estimate survival by averaging outcomes of 
10,000 trials for each transplant strategy. The values and ranges of parameters in the 
model were obtained from the United Network for Organ Sharing (UNOS) and the 
Scientiﬁc Registry of Transplant Recipients (SRTR) data and published literature. 
RESULTS: The model demonstrates a mean survival of 67.6 months and 61.6 months 
for SLK and LTA recipients, respectively. Of the 10,000 trials, 4,181 isolated kidney 
transplants were performed when using the LTA strategy. The SLK transplant recipient 
survival was 6.1 months longer than LTA recipient survival. However, this SLK 
survival beneﬁt occurred at the expense of an additional 69.3 kidney grafts per 100 
SLK transplants performed when compared with LTA. CONCLUSIONS: An addi-
tional 69.3 kidney grafts per 100 SLK transplants are required to achieve a 6.1 month 
improvement in survival for SLK transplant recipients.
PUK4
EFFECT OF ATYPICAL ANTIPSYCHOTICS ON URINARY 
INCONTINENCE IN US NURSING HOME RESIDENTS USING 
PSYCHOTROPIC MEDICATIONS
Khokhawalla I1, Wu WK2
1St. John’s University, Fresh Meadows, NY, USA, 2St.John’s University, Queens, NY, USA
OBJECTIVES: Psychotropics have been widely used in nursing homes. Case reports 
and review articles have implicated that atypical antipsychotics may enhance the risk 
of urinary incontinence (UI); a condition prevalent in more than half the nursing home 
residents (NHR). With antipsychotics being the most extensively prescribed psycho-
tropic medication in nursing homes, the objective of this study was to investigate the 
effect of atypical antipsychotics on UI in NHR using psychotropic medications. 
METHODS: The 2004 National Nursing Home Survey (NNHS) was used as the data 
source. Logistic regression was performed to determine relationship between UI and 
use of atypical antipsychotics, in presence of other covariates. Sample data was 
weighted and data analysis was performed using SAS 9.1. RESULTS: From the origi-
nal 13507 NNHS residents, 64.57% (n = 8722) used psychotropic medications; of 
which 27.22% (n = 2366) used atypical antipsychotics and 57.58% (n = 5005) were 
incontinent. Among those using psychotropics, incontinent residents were older than 
their continent counterparts (81.48 ± 12.01years versus 77.45 ± 13.67years, p < 
.0001). Regression analysis shows that residents on atypical antipsychotics had 81.5% 
increased risk of being incontinent (OR = 1.815, p < 0.0001). Concomitant use of 
other medications which may increase incontinence risk was not signiﬁcantly associ-
ated with UI (p = 0.1016). Presence of comorbidities enhanced UI risk by 58.9% (OR 
= 1.589, p < .0001). Residents who were ADL dependent (OR = 1.224, p < .0001) or 
used bedrails (OR = 1.264, p < 0.0157), chairs (OR = 1.708, p < 0.0118) or truncal 
restraints (OR = 1.501, p < 0.0238) also had higher risks of being incontinent. Advanc-
ing age (OR = 1.022, p < 0.0001) and female gender (OR = 1.160, p = 0.0353) were 
also found to be other risk factors. CONCLUSIONS: The study results indicate that 
use of atypical antipsychotics leads to increased UI risk. Since coping with UI continues 
to be a challenge in elderly population, newer antipsychotic medications should be 
developed to ensure safer treatments. In addition, closely monitoring the resident’s 
functional status and use of physical restraints would also help minimize incontinence 
episodes.
PUK5
DOES RACIAL VARIATION IN RISK FACTORS HAVE A ROLE TO PLAY 
IN THE INCIDENCE OF CHRONIC KIDNEY DISEASE IN THE US 
POPULATION
Shah J, Nair R
St.John’s University, Jamaica, NY, USA
OBJECTIVES: To compare racial variations in risk factors associated with incidence 
of Chronic Kidney Disease (CKD) in a sample population (age >11 years) and look for 
possible early indicators. METHODS: A retrospective study was conducted using the 
NHANES 2003–2004 database comprising of a nationally representative sample con-
taining nutritional and health records. Patients were screened on the basis of their 
Glomerular ﬁltration rates and a sample with an estimated Glomerular Filtration Rate 
(eGFR) <60ml/min/1.73m2 was included in the study. The eGFR was calculated using 
the 6-variable MDRD equation. Demographics and laboratory records such as Blood 
Pressure, cholesterol, glucose, albumin, serum creatinine and Vitamin D levels were 
recorded. RESULTS: An eGFR <60 ml/min/1.73m2 was observed in 413 (5.6%) of 
7344 NHANES participants; of which 71.16% were Non-Hispanic Whites, 10.89% 
were African-Americans and 11.13% were Mexican Americans. Lower prevalence 
amongst African-Americans and Mexican-Americans was not seen to be uniform in 
higher stages of CKD. Vitamin D deﬁciency was noticeable in African-Americans and 
Mexican Americans compared to Non-Hispanic Whites at 15.28ng/ml (95% CI 12.82–
17.74), 17.17ng/ml (95% CI 14.87–19.47) and 24.46ng/ml (95% CI 23.46–25.47) 
respectively. Serum Creatinine levels were recorded as 1.717mg/dl (95% 
CI 1.287–2.147), 2.351mg/dl (95% CI 1.565–3.136) and 1.355mg/dl (95% CI 
1.303–1.406) for Mexican-Americans, African-Americans and Non-Hispanic Whites 
respectively. CONCLUSIONS: Higher prevalence of African-Americans and Mexican-
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Americans participants in the later stages of CKD may be associated with lack of health 
care access/ socio-economic factors. The proportion of population suffering from 
hypertension and diabetes increased signiﬁcantly from stage 1 to stage 5 along with 
marked racial disparities in the higher stages of CKD. Markers such as Vitamin D 
deﬁciency, Hypertension & serum creatinine levels can be better monitored by regular 
blood tests and prove to be effective early indicators in the progression of CKD.
URINARY/KIDNEY DISORDERS – Cost Studies
PUK6
FIVE-YEAR BUDGET IMPACT ANALYSIS OF ONCE-DAILY VERSUS 
TWICE-DAILY TACROLIMUS, IN PATIENTS UNDERGOING RENAL 
TRANSPLANT IN THE UNITED KINGDOM
Sidhu M1, Lees L2, Warner J2
1Astellas Pharma Europe Ltd, Staines, Middlesex, UK, 2Abacus International, Bicester, 
Oxfordshire, UK
OBJECTIVES: Non-adherence to immunosuppressants increases risk of late acute 
rejection (AR) episodes, a known predictor of graft loss, which is associated with 
re-transplantations, dialysis and increased mortality. Once-daily immunosuppressant 
formulations demonstrate higher patient adherence than multiple daily dose therapies 
and may lead to fewer AR episodes and graft losses. A model was constructed to 
estimate the ﬁve-year impact of potentially improved adherence in new renal trans-
plant recipients receiving once- rather than twice-daily tacrolimus. METHODS: The 
increased potential for sufﬁcient adherence with once-daily immunosuppressants, 
versus twice-daily, is reported as an odds ratio (OR) of 2.35 (published literature). 
The model uses a probability of sufﬁcient adherence of 74% with once-daily tac-
rolimus, determined from an assumed adherence for twice-daily tacrolimus of 55% 
and OR for adherence with once- versus twice-daily therapy. Increased adherence is 
assumed to improve consistency in tacrolimus exposure, reducing AR each year post-
transplant and improving graft survival. Sufﬁcient levels of expected adherence with 
once- and twice-daily tacrolimus are used to model ﬁve-year survival rates for: AR 
(sufﬁciently-adherent versus non-sufﬁciently-adherent patients); graft survival (no pre-
vious AR versus previous AR); patient survival (functioning graft versus dialysis). Drug 
costs include tacrolimus; co-prescribed therapies (IV and oral prednisolone and oral 
mycophenolate mofetil). Other resource use and costs considered include management 
of AR; dialysis after graft loss; re-transplantation. RESULTS: Over ﬁve years, assum-
ing 100 new renal transplant recipients annually, once-daily tacrolimus is associated 
with fewer AR episodes than twice-daily (8.4 and 10.5, respectively), due to improved 
sufﬁcient adherence. Once-daily tacrolimus yields cumulative cost savings of £104,534, 
including savings in drug acquisition (£69,180); management of AR (£22,837); re-
transplantation (£417); dialysis (£13,631). CONCLUSIONS: Use of once- rather than 
twice-daily tacrolimus reduces incidence of AR and could yield clinical improvements 
and cost savings over ﬁve-years.
PUK7
IMMUNOSUPPRESSANT THERAPY PATTERNS AND ITS COSTS IN POST 
KIDNEY TRANSPLANT PATIENTS IN THE NATIONAL TRANSPLANT 
PROGRAM IN BRAZIL
Tedesco-Silva Jr H1, Manfro RC2, Asano E3, Nita ME3, Carvalho F3, Dan S4, Donato BM5, 
Rahal E3, The KIT73 STUDY GROU P3
1Fundação Oswaldo Ramos - Hospital do Rim e Hipertensão, São Paulo, São Paulo, Brazil, 
2Hospital de Clínicas de Porto Alegre, São Paulo, São Paulo, Brazil, 3Bristol-Myers Squibb 
S/A, São Paulo, São Paulo, Brazil, 4New BD Assessoria Empresarial LTDA, São Paulo, São 
Paulo, Brazil, 5Bristol-Myers Squibb Co, Wallingford, CT, USA
OBJECTIVES: Immunosuppressive drugs (IS) are used in combination/schemes to 
achieve optimal regimen of immunosupression, increasing graft and recipient survival 
rates in post kidney transplant patients. The aim of this study is to determine immu-
nosuppressant treatment patterns and associated costs in kidney transplant patients 
from the Brazilian National Transplant Program. METHODS: A review of the entire 
government administrative claim database (Outpatient Information System – SIA/
DATASUS) was conducted from 2005 to 2008, to determine yearly expenses (in 2008 
USD) with each IS combination. In order to assess the dynamics of the combinations 
used, a subset of this population, all patients from 7 hospitals who underwent kidney 
transplantation in 2004, was followed from January 2005 to December 2007 to 
estimate calcineurin inhibitors (CNI) switching rate and treatment adherence in terms 
of 24-month medication possession ratio (MPR). RESULTS: Analysis of the entire 
database reveals that overall IS expenses in kidney transplant patients more than 
doubled, from US$62,429,359 in 2005 to US$126,874,381 in 2008, mostly due to an 
increase in both treatment volume and costs from 2006 to 2007. From 2005 to 2007, 
monthly treatment volume increased 14.7% for cyclosporine and 62.9% for tac-
rolimus, whereas costs increased 3.2% for cyclosporine and 93.1% for tacrolimus. 
The highest ﬁnancially impacting combination per CNI were tacrolimus plus myco-
phenolate sodium (US$37,329,606 in 2008), and cyclosporine plus mycophenolate 
sodium (US$10,163,990 in 2008). A total of 540 patients were eligible for the sub-
population analysis. CNI therapy switch rate, from tacrolimus to cyclosporine or 
vice-versa was 4.3% (n = 185). MPR for CNIs was 73.7% (n = 224; SD = 21.7%). 
CONCLUSIONS: From 2005 to 2008, IS drugs expenses in post kidney transplant 
patients substantially increased in Brazil. Low CNI switching rates suggests that de 
novo patients are the main target population for newer CNIs. The poor drug adher-
ence detected is an important point of concern.
PUK8
ERYTHROPOIESIS-STIMULATING AGENTS UTILIZATION AND COSTS 
IN PATIENTS WITH CHRONIC KIDNEY DISEASE NOT ON DIALYSIS 
FROM TWO LARGE CLAIMS DATABASES
Lafeuille MH1, Bailey RA2, Laliberté F1, Senbetta M2, Blacksmith A1, Lefebvre P1
1Groupe d’analyse, Ltée, Montreal, QC, Canada, 2Centocor Ortho Biotech Services, LLC, 
Horsham, PA, USA
OBJECTIVES: This study evaluated recent erythropoiesis-stimulating agent (ESA) 
utilization and costs from 2 large health insurance claims databases in chronic kidney 
disease (CKD) patients not on dialysis. METHODS: An analysis of recent medical 
claims from the Ingenix IMPACT (January 2006-March 2009) and Medicare 5% 
(January 2005-December 2007) databases was conducted. Patients ≥18 years, newly 
initiated on epoetin alfa (EPO) or darbepoetin alfa (DARB), with ≥1 claim for CKD 
and ≥2 ESA claims were included. Patients diagnosed with cancer, receiving chemo-
therapy or dialysis, or receiving both agents were excluded. Mean cumulative ESA 
dose was used to calculate drug cost (using October 2009 wholesale acquisition cost) 
and dose ratio (Units EPO: mcg DARB). Multivariate analysis was also conducted to 
assess adjusted cost differences between the two agents. RESULTS: A total of 4,678 
ESA-treated patients were identiﬁed (IMPACT—EPO: 991, DARB: 689; Medicare—
EPO: 1,788, DARB 1,210). Age and gender distributions were similar between 
the 2 groups (Mean age: IMPACT: 63.9 vs. 63.2 yrs; Medicare: 74.7 vs. 74.2 yrs, P 
= NS; % women: IMPACT: 49% vs. 54%; Medicare 59% vs. 62%, P = NS). ESA 
treatment duration was also similar for EPO and DARB patients. The mean cumulative 
dose [SD] was 164,786 [175,453] and 244,718 [304,839] Units for EPO and 
694 [690] and 989 [1,118] mcg for DARB, resulting in dose ratios of 237:1 and 247:1 
for IMPACT and Medicare data, respectively. Based on the recent utilization of 
ESAs, cumulative cost was 44% and 38% higher for DARB than EPO (IMPACT—
EPO $2380; DARB $3427; Medicare—EPO $3534; DARB $4888). After adjusting 
for covariates, cumulative drug costs remained signiﬁcantly higher for DARB. 
CONCLUSIONS: Based on large health insurance claims databases, this observational 
study of recent ESA utilization in CKD patients not on dialysis reported dose 
ratios of 237:1 and 247:1 and cost premiums of 44% and 38% associated with 
DARB.
PUK9
SEVEN YEAR TRENDS OF PHARMACY BENEFIT ERYTHROPOIESIS-
STIMULATING AGENT UTILIZATION AND COST CONSIDERATIONS OF 
CHRONIC KIDNEY DISEASE PATIENTS NOT ON DIALYSIS
Vekeman F1, Bailey RA2, Laliberté F3, Senbetta M2, McKenzie RS2, Lefebvre P3
1Analysis Group, Inc., Washington , DC, USA, 2Centocor Ortho Biotech Services, LLC, 
Horsham, PA, USA, 3Groupe d’analyse, Ltée, Montreal, QC, Canada
OBJECTIVES: This study compared drug utilization patterns and associated costs as 
well as dosing trends over time in patients with chronic kidney disease (CKD) not on 
dialysis receiving epoetin alfa (EPO) or darbepoetin alfa (DARB) through a pharmacy 
beneﬁt. METHODS: An analysis of pharmacy claims between July 2002 and March 
2009 from the Ingenix IMPACT database was conducted. Patients ≥18 years, newly 
initiated on erythropoiesis-stimulating agents (ESAs), with ≥1 claim for CKD, and ≥1 
ESA pharmacy claim were included. Patients diagnosed with cancer, receiving chemo-
therapy or dialysis, or receiving both agents were excluded. Mean cumulative ESA 
dose was used to calculate drug cost (using 10/2009 wholesale acquisition cost) and 
dose ratio (Units EPO: mcg DARB). Average weighted weekly ESA dose was calculated 
during the treatment episode to assess ESA utilization trends over time. Multivariate 
analysis was also conducted. RESULTS: A total of 4,202 ESA-treated patients were 
identiﬁed (EPO 3,111; DARB 1,091). EPO patients were slightly older (60.1 vs. 57.0, 
P < .001) with a higher Charlson Comorbidity Index (1.68 vs 1.44, P < .001). Mean 
[SD] cumulative dose was 219,060 [236,830] Units for EPO and 818 [956] mcg for 
DARB, resulting in a dose ratio of 268:1 (Units EPO: mcg DARB). The corresponding 
drug cost was 28% higher for DARB than EPO ($3163 vs. $4039, P < .001). 
From 2002 to 2009, a decreasing trend was observed in semi-annual mean weekly 
doses of ESAs [EPO: 17,053 to 13,674 Units (25% decrease); DARB: 63 to 51 mcg 
(20% decrease)]. After adjusting for potential confounding factors, the DARB cost 
premium and the decreasing weekly ESA dosing trend over time remained signiﬁcant. 
CONCLUSIONS: This study of CKD patients not on dialysis receiving ESAs through 
pharmacy beneﬁts reported signiﬁcantly higher drug costs in the DARB group 
compared with the EPO group and a decreasing ESA dosing trend during the 7-year 
study period.
PUK10
IMPROVED RESOURCE UTILIZATION OUTCOMES ASSOCIATED WITH 
PREDIALYSIS USE OF PARICALCITOL FOR SECONDARY 
HYPERPARATHYROIDISM (SHPT)
Marx S1, Frye CB2, Khan SS1, Harshaw Q2, Audhya P1, Deering K2, Sterz R1
1Abbott, Abbott Park, IL, USA, 2EPI-Q, Inc., Oak Brook, IL, USA
OBJECTIVES: The objective of this study is to evaluate hospitalizations, outpatient 
services and medication use in the ﬁrst year of dialysis associated with pre-dialysis 
treatment with paricalcitol compared to no predialysis vitamin D receptor (VDR) 
activator use in chronic kidney disease (CKD) patients with SHPT. METHODS: A 
matched cohort analysis was conducted in 154 hemodialysis patients comparing uti-
lization outcomes of predialysis use of paricalcitol compared to no VDR activator 
treatment, using the Medstat™ administrative claims database from 2000–2007. 
Patients were matched using propensity scoring for age, gender, Charlson co-morbid-
ity Index, and pre-index total costs. Multivariate models adjusted for age, gender, 
